Importantly, genetic knockdown of TREM2 or pharmacologic blockade of its downstream kinases significantly mitigates MNT formation, reduces the integration of these cells into tumor-associated neural networks, and correlates with alleviation of chronic cancer-associated pain in preclinical models [77]. The gene discussed is TREM2; the disease is neoplasm.